论文部分内容阅读
目的:观察生脉饮口服液治疗小儿扩张型心肌病临床疗效。方法:我院儿科74例扩张型心肌病患儿(2013年1月至2015年12月)为对象,将其随机分为2组,均给予常规方案治疗,其中观察组另给予生脉饮口服液,分析该生脉饮口服液对该疾病是否有益。结果:(1)观察组治疗后的总有效率为91.89%,高于对照组70.27%。治疗后,观察组LVEF、LVSD、LVDD分别为(45.13±3.27%、40.95±2.26mm、42.95±2.14mm),均明显优于对照组(40.18±3.16%、45.08±2.35mm、47.23±2.30mm)。(3)治疗后,观察组SDNN、SDANN、r MSDD、p NN50分别为(127.9±7.8ms、119.4±7.2ms、29.31±2.52ms、17.35±1.04%),均明显高于对照组(115.8±7.1ms、104.5±6.9ms、25.82±2.44ms、13.28±0.98%)。(4)观察组不良反应率为5.41%,略低于对照组13.51%,但组间差异无统计学意义。(5)治疗开始起1年内,对照组死亡6例(16.22%),和观察组5例(13.51%)比,差异无统计学意义。结论:生脉饮口服液可改善扩张型心肌病患儿心功能,增加治疗效果,且用药安全。
Objective: To observe the therapeutic effect of Shengmaiyin oral liquid on dilated cardiomyopathy in children. Methods: A total of 74 pediatric patients with dilated cardiomyopathy (January 2013 to December 2015) were enrolled in this study. They were randomly divided into two groups, all of whom were given conventional regimen. The observation group was given Sheng Mai Yin Liquid, analyze the Shengmai drink oral liquid beneficial to the disease. Results: (1) The total effective rate of the observation group after treatment was 91.89%, which was higher than that of the control group (70.27%). After treatment, the LVEF, LVSD and LVDD in the observation group were significantly higher than those in the control group (45.13 ± 3.27%, 40.95 ± 2.26mm, 42.95 ± 2.14mm, 40.18 ± 3.16%, 45.08 ± 2.35mm, 47.23 ± 2.30mm ). (3) After treatment, SDNN, SDANN, MSDD and p NN50 in the observation group were significantly higher than those in the control group (115.9 ± 7.8ms, 119.4 ± 7.2ms, 29.31 ± 2.52ms and 17.35 ± 1.04% 7.1 ms, 104.5 ± 6.9 ms, 25.82 ± 2.44 ms, 13.28 ± 0.98%). (4) The adverse reaction rate in the observation group was 5.41%, slightly lower than that in the control group (13.51%), but there was no significant difference between the two groups. (5) Within one year after the start of treatment, there were 6 deaths (16.22%) in control group and 5 cases (13.51%) in observation group, the difference was not statistically significant. Conclusion: Shengmaiyin oral liquid can improve cardiac function in children with dilated cardiomyopathy, increase the therapeutic effect, and medication safety.